Clinical Trials for PF-02341066
2 Open Trials
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | VICCTHO1079 07/27/2011 | Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated Patients with Non-Squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus |
| Therapeutic | COGADVL0912 04/05/2011 | PH 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-MET, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
